StockNews.com began coverage on shares of Encompass Health (NYSE:EHC – Get Rating) in a research note released on Thursday morning. The brokerage issued a hold rating on the stock.
Several other equities analysts have also commented on the company. UBS Group increased their price objective on Encompass Health from $68.00 to $73.00 in a research report on Wednesday, February 8th. Truist Financial increased their price objective on Encompass Health from $70.00 to $75.00 and gave the company a buy rating in a research report on Thursday, February 9th. TheStreet upgraded Encompass Health from a c+ rating to a b- rating in a research report on Wednesday, December 21st. Stephens restated an overweight rating and set a $70.00 price target on shares of Encompass Health in a research report on Wednesday, February 8th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Encompass Health from $62.00 to $70.00 in a research report on Thursday, February 9th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Encompass Health has an average rating of Moderate Buy and an average price target of $69.00.
Encompass Health Price Performance
Shares of Encompass Health stock opened at $51.55 on Thursday. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.50. The firm has a market capitalization of $5.14 billion, a PE ratio of 19.09, a price-to-earnings-growth ratio of 1.23 and a beta of 1.04. The business’s 50-day moving average price is $59.30 and its 200-day moving average price is $55.51. Encompass Health has a 12 month low of $44.33 and a 12 month high of $74.61.
Encompass Health Dividend Announcement
Insiders Place Their Bets
In other Encompass Health news, CFO Douglas E. Coltharp sold 17,895 shares of the stock in a transaction that occurred on Friday, February 10th. The stock was sold at an average price of $60.78, for a total value of $1,087,658.10. Following the completion of the sale, the chief financial officer now owns 53,097 shares in the company, valued at approximately $3,227,235.66. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.70% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. lifted its stake in shares of Encompass Health by 43.4% in the 3rd quarter. Prudential Financial Inc. now owns 16,285 shares of the company’s stock valued at $751,000 after purchasing an additional 4,925 shares during the period. Sei Investments Co. lifted its stake in shares of Encompass Health by 29.4% in the 2nd quarter. Sei Investments Co. now owns 213,253 shares of the company’s stock valued at $12,010,000 after purchasing an additional 48,456 shares during the period. Mackenzie Financial Corp purchased a new position in Encompass Health during the second quarter valued at $289,000. Mitsubishi UFJ Trust & Banking Corp raised its stake in Encompass Health by 12.4% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 8,996 shares of the company’s stock valued at $504,000 after buying an additional 995 shares during the last quarter. Finally, Aptus Capital Advisors LLC purchased a new position in Encompass Health during the third quarter valued at $1,788,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.
Encompass Health Company Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.